ClinicalTrials.gg
Not yet recruitingNCT07943364Updated Nov 17, 2026

Transcutaneous Auricular Vagus Nerve Stimulation in Perimenopause

An interventional study of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) and Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Perimenopausal Disorder, sponsored by Spaulding Rehabilitation Hospital. Not yet recruiting. Open to female participants aged 35 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Spaulding Rehabilitation Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
35 Years to 60 Years
Sex
Female
01

Study summary

The study will test an ear-based nerve stimulation (taVNS) to see if it can ease common perimenopause symptoms like hot flashes, poor sleep, mood changes, and "brain fog". Along the way, brain activity (EEG) and heart rhythm patterns (HRV) will be tracked to find simple, reliable signs of improvement.

Because women with both mild and more severe symptoms early in the transition are included, the results can learn who benefits most and why. If successful, this study will set the stage for larger trials and could make taVNS a low-risk, affordable option to support women's brain and overall health during perimenopause.

02

Conditions studied

  • Perimenopausal Disorder
03

In context

Lead sponsor

Spaulding Rehabilitation Hospital is the lead sponsor of 118 studies on the registry; 27 are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 17 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Perimenopausal women aged 35-60 with climacteric symptoms for >6 months, irregular menstruation, and at least one menses in the past 6 months.
  • Women on menopausal hormone therapy (HRT).
  • Ability to understand procedures and provide .
  • Willingness to complete study visits, questionnaires, EEG/HRV recordings, taVNS sessions.
  • Negative urine pregnancy test.
  • Access to stable internet for remote sessions or willingness to use study-provided equipment.

Exclusion criteria

Exclusion criteria:

  • Pregnancy, breastfeeding, or planning pregnancy during the active study period (for randomized subjects).
  • status.
  • History of implanted stimulator.
  • unstable cardiac disease.
  • History of seizure disorder or serious neurological condition that interferes with study procedures or EEG interpretation.
  • Current ear infection.
  • Active severe psychiatric instability.
  • Recent initiation or major dose change of hormone therapy, psychotropics, beta-blockers, anticholinergics, or other medications likely to substantially affect autonomic or symptom outcomes.
  • Current participation in another interventional trial that could confound outcomes.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Active Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

    Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

  • Placebo comparator
    Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

    Device: Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

Interventions

  • DeviceTranscutaneous Auricular Vagus Nerve Stimulation (taVNS)

    Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation technique that delivers mild electrical stimulation to the external ear at regions innervated by the auricular branch of the vagus nerve.

  • DeviceSham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

    tAVNS device with electrode placed at the external ear at regions with no active current.

06

What researchers measure

Primary outcomes

  1. Electroencephalography (EEG)

    Resting Electroencephalography (EEG) will be recorded using a 64-channel system (resting alpha/theta power)

    Time frame: Baseline (Visit 2, pre-intervention) and Post Intervention (Visit 13, around 2 weeks from V2)

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jun 2028, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07943364
Responsible party
Anna Carolyna Lepesteur Gianlorenco (Instructor/ Investigator, Spaulding Rehabilitation Hospital) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion